Choosing a First-Line Combination Treatment Regimen for Renal Cell Carcinoma

Video

Drs Rana McKay and Tom Powles debate the merits of different first-line combination treatment regimens for renal cell carcinoma.

Thomas Powles, MBBS, MRCP, MD: The question I’m always asked on these podcasts or videos is which treatment do you use? Which do you select? Why?

Rana McKay, MD: Good question. It varies. We chatted a lot about I/O [immuno-oncology]–TKI [tyrosine kinase inhibitor] combinations. There are also I/O–I/O combos. We have over 5 years of follow-up data from the nivolumab-ipilimumab data, which show durability of response. The tail on the curve is hanging around 30% and continues to be consistent. There are 2 strategies. Do you need to play the short game, or do you need to play the long game? As I’m counseling patients about that, and as we think about choices in the clinic with nivolumab-ipilimumab, we’re largely playing the long game. Not that I want to compare, but the durability of that regimen is incredibly attractive.

But some individuals need to play the short game because they won’t have a long game. Patients who have an almost visceral crisis need to have a response. That’s where an I/O–VEGF comes in nicely. As we think about the nivolumab-ipilimumab data, while you have that 30% tail, about 1 of 5, 18%, are going to have primary PD. We don’t know who they are. We don’t know how to identify who those individuals are to not give them nivolumab-ipilimumab. These are questions that are in the field, but that’s how I try to strategize around it.

Lenvatinib-pembrolizumab is highly effective. I like to use that regimen in patients who have potentially locally advanced unresectable disease. I want an immediate short-term response to get them resected. That’s the perfect population because the response rate is so high and the primary PD rate is so low. That’s where I like to use this regimen.

Thomas Powles, MBBS, MRCP, MD: My thoughts are similar. For centers that are treating a handful of patients each year, rather than dozens of patients, it’s probably easier to pick 1 regimen and stick with it. I agree that nivolumab-ipilimumab is not for all patients. If you’re going to pick 1 regimen, it’s probably easier to use a VEGF TKI–I/O. There are some patients I’d give nivolumab-ipilimumab to. For example, patients with intermediate-risk disease and perhaps low-volume metastases, where I wouldn’t be worried if they got primary progression of disease. Those patients would be good candidates for nivolumab-ipilimumab.

We’ve talked about the good-risk patient. We know they can’t have nivolumab-ipilimumab; it’s not licensed. It’s a bit nuanced. But there’s nothing wrong with using VEGF TKI–I/O in unselected patients. All 3 regimens have attractive features. Pembrolizumab has a 0.53 hazard ratio, which came out first. People like axitinib; it has a short half-life. The lenvatinib-pembrolizumab data efficacy data look unbeatable from a PFS [progression-free survival] and response perspective. Everyone likes cabozantinib. Everyone likes nivolumab. Of course, the cabozantinib dose at 40 mg is attractive, and there are some good quality-of-life data as well. So you could make an argument for any of the 3 regimens. Picking 1 and using it well makes sense to me.

Rana McKay, MD: I completely agree with you. The dose modifications around the TKIs can get challenging. Having a strategy and a game plan is key to optimizing use for a clinician.

Transcript edited for clarity.

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Related Content
Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

Hereditary Renal Tumor Syndromes and the Use of mTOR Inhibitors

José Luis Rodríguez-Olivares, MD;Héctor Raúl González-Sánchez, MD;Evelyn Lilian Beas-Lozano, MD;Jazmin Arteaga-Vázquez, MD;Elaine T. Lam, MD;María T. Bourlon, MD, MSc, FASCO
October 22nd 2024
Article

A 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Exploring New Possibilities in Kidney Cancer Detection and Therapy

Karl Semaan, MD, MSc ;Neil J. Shah, MBBS;Bradley McGregor, MD
July 22nd 2024
Podcast

Experts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.

Belzutifan Yields Sustained Responses, PFS in Advanced Clear Cell RCC | Image Credit: © Rasi - stock.adobe.com.

Belzutifan Yields Sustained Responses, PFS in Advanced Clear Cell RCC

Caroline Seymour
September 13th 2024
Article

Final analysis data from LITESPARK-005 support belzutifan as a treatment for patients with previously treated advanced clear cell RCC.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

Enfortumab Vedotin Combo Gains European Approval for Urothelial Cancer

Roman Fabbricatore
August 29th 2024
Article

The decision follows phase 3 EV-302 trial findings showing improved survival with enfortumab vedotin plus pembrolizumab vs chemotherapy in urothelial cancer.

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.

Exercise Oncology May Improve HRQOL in Metastatic RCC

Ariana Pelosci
July 30th 2024
Article

Patients receiving immune checkpoint inhibitors for renal cell carcinoma had improved symptom burden when enrolled in a remote exercise program.